A surprising revelation has emerged from a Rutgers-led study, published in The Journal of Clinical Endocrinology & Metabolism, that challenges conventional wisdom about diabetes management. The study suggests that a commonly prescribed diabetes drug, metformin, might be hindering one of the most trusted methods for preventing the disease: exercise.
This is a controversial finding, as it goes against the common belief that combining two effective treatments should yield even better results. But here's where it gets interesting: the research indicates that metformin may be reducing the very benefits that exercise brings to individuals at risk of metabolic syndrome, a precursor to diabetes and heart disease.
To test this theory, Professor Steven Malin and his team conducted a trial involving 72 adults with metabolic syndrome risk factors. They divided the participants into four groups, each engaging in either high- or low-intensity exercise, with or without metformin. Over 16 weeks, the researchers tracked changes in blood vessel function, a critical aspect of diabetes management.
The results were eye-opening. Exercise alone improved vascular insulin sensitivity, allowing blood vessels to respond better to insulin and increase blood flow to muscles. This is crucial for regulating blood sugar levels after meals. However, when metformin was introduced, these improvements were diminished. The drug also reduced gains in aerobic fitness and had a negative impact on inflammation and fasting glucose levels.
"Exercise training, regardless of intensity, improved blood vessel function," Malin explained. "But metformin seemed to blunt this effect, suggesting that neither exercise intensity nor the drug alone is optimal for blood vessel health."
This has significant implications for diabetes treatment, as exercise is a key component in managing blood sugar and improving physical function. If metformin interferes with these benefits, patients may not receive the protection they need to lower their disease risk.
The implications extend beyond the lab. Fitness gains from exercise translate into increased energy for daily activities, such as climbing stairs or playing with children. If these improvements are hindered, quality of life can suffer.
Malin emphasizes that these findings do not suggest stopping metformin or exercise. Instead, they highlight the need for further research and closer monitoring by doctors when combining these treatments. The goal is to find strategies that preserve the benefits of both.
The reason for metformin's interference with exercise benefits is still unclear. Malin suggests it may be related to the drug's mechanism of action, which involves blocking parts of the mitochondria, thereby reducing oxidative stress and improving blood sugar control. However, this same mechanism may also interfere with the cellular adaptations triggered by exercise, such as improved mitochondrial function and aerobic capacity.
Previous research has hinted at similar effects, but this trial is among the first to specifically examine vascular insulin sensitivity, a critical factor in glucose regulation and cardiovascular health. By demonstrating that metformin can blunt improvements in both large arteries and tiny capillaries, regardless of exercise intensity, the study underscores the complexity of combining these treatments.
The stakes are high, as Type 2 diabetes affects millions worldwide. Prevention strategies often rely on lifestyle changes combined with medication. If these strategies fall short, patients may face increased long-term risks.
"We need to find the best way to recommend exercise alongside metformin," Malin said. "We also need to understand how other medications interact with exercise to develop better guidelines for doctors to help people reduce their chronic disease risk."
This study involved a collaborative effort from Rutgers researchers, including Professor Sue Shapses, Professor Andrew Gow, Assistant Professor Ankit Shah, former post-doctoral fellow Tristan Ragland, project scientist and clinical coordinator Emily Heiston, and former doctoral student Daniel Battillo.
